“Dr. Lechleiter said this plan would have ‘catastrophic consequences’ for the American pharmaceutical industry, estimating that it would cost the industry somewhere between $100 billion and $135 billion,” National Center for Public Policy Research Free Enterprise Project director Justin Danhof, who was present at the Eli Lilly shareholders meeting, said in a statement. “Enacting Obama’s plan would rip billions from innovation and dearly cost American patients. Using $100 billion in additional costs as a baseline, he said drug companies would spend $15 billion less on drug innovation — an unacceptable cut.”
via Drug company that supported Obamacare now says rebate plan could be ‘catastrophic’